FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970433797> ?p ?o ?g. }

• W1970433797 endingPage "1713" @default.
• W1970433797 startingPage "1706" @default.
• W1970433797 abstract "Introduction:Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been characterized in a subset of patients with advanced non-small cell lung cancer (NSCLC). Patients harboring these mutations in their tumors show excellent response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The EGFR-TKI gefitinib has been approved in Europe for the treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of the EGFR TK. Because EGFR mutation testing is not yet well established across Europe, biomarker-directed therapy only slowly emerges for the subset of NSCLC patients most likely to benefit: those with EGFR mutations.Methods:The “EGFR testing in NSCLC: from biology to clinical practice” International Association for the Study of Lung Cancer-European Thoracic Oncology Platform multidisciplinary workshop aimed at facilitating the implementation of EGFR mutation testing. Recommendations for high-quality EGFR mutation testing were formulated based on the opinion of the workshop expert group.Results:Co-operation and communication flow between the various disciplines was considered to be of most importance. Participants agreed that the decision to request EGFR mutation testing should be made by the treating physician, and results should be available within 7 working days. There was agreement on the importance of appropriate sampling techniques and the necessity for the standardization of tumor specimen handling including fixation. Although there was no consensus on which laboratory test should be preferred for clinical decision making, all stressed the importance of standardization and validation of these tests.Conclusion:The recommendations of the workshop will help implement EGFR mutation testing in Europe and, thereby, optimize the use of EGFR-TKIs in clinical practice. Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have recently been characterized in a subset of patients with advanced non-small cell lung cancer (NSCLC). Patients harboring these mutations in their tumors show excellent response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). The EGFR-TKI gefitinib has been approved in Europe for the treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of the EGFR TK. Because EGFR mutation testing is not yet well established across Europe, biomarker-directed therapy only slowly emerges for the subset of NSCLC patients most likely to benefit: those with EGFR mutations. The “EGFR testing in NSCLC: from biology to clinical practice” International Association for the Study of Lung Cancer-European Thoracic Oncology Platform multidisciplinary workshop aimed at facilitating the implementation of EGFR mutation testing. Recommendations for high-quality EGFR mutation testing were formulated based on the opinion of the workshop expert group. Co-operation and communication flow between the various disciplines was considered to be of most importance. Participants agreed that the decision to request EGFR mutation testing should be made by the treating physician, and results should be available within 7 working days. There was agreement on the importance of appropriate sampling techniques and the necessity for the standardization of tumor specimen handling including fixation. Although there was no consensus on which laboratory test should be preferred for clinical decision making, all stressed the importance of standardization and validation of these tests. The recommendations of the workshop will help implement EGFR mutation testing in Europe and, thereby, optimize the use of EGFR-TKIs in clinical practice." @default.
• W1970433797 created "2016-06-24" @default.
• W1970433797 creator A5001928949 @default.
• W1970433797 creator A5007889470 @default.
• W1970433797 creator A5012411744 @default.
• W1970433797 creator A5013804417 @default.
• W1970433797 creator A5016904876 @default.
• W1970433797 creator A5024585720 @default.
• W1970433797 creator A5030453966 @default.
• W1970433797 creator A5030827550 @default.
• W1970433797 creator A5036091074 @default.
• W1970433797 creator A5044573499 @default.
• W1970433797 creator A5044887899 @default.
• W1970433797 creator A5045442138 @default.
• W1970433797 creator A5046602426 @default.
• W1970433797 creator A5052004079 @default.
• W1970433797 creator A5056605049 @default.
• W1970433797 creator A5062227589 @default.
• W1970433797 creator A5063926074 @default.
• W1970433797 creator A5071851332 @default.
• W1970433797 date "2010-10-01" @default.
• W1970433797 modified "2023-10-14" @default.
• W1970433797 title "Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop" @default.
• W1970433797 cites W152953340 @default.
• W1970433797 cites W1967394241 @default.
• W1970433797 cites W1969800769 @default.
• W1970433797 cites W1970738520 @default.
• W1970433797 cites W2002937040 @default.
• W1970433797 cites W2003984225 @default.
• W1970433797 cites W2009481811 @default.
• W1970433797 cites W2016525663 @default.
• W1970433797 cites W2016717983 @default.
• W1970433797 cites W2036189924 @default.
• W1970433797 cites W2038263620 @default.
• W1970433797 cites W2038433128 @default.
• W1970433797 cites W2043587877 @default.
• W1970433797 cites W2043696829 @default.
• W1970433797 cites W2049484790 @default.
• W1970433797 cites W2069312070 @default.
• W1970433797 cites W2081269875 @default.
• W1970433797 cites W2092669109 @default.
• W1970433797 cites W2093922887 @default.
• W1970433797 cites W2095618958 @default.
• W1970433797 cites W2101329867 @default.
• W1970433797 cites W2109897091 @default.
• W1970433797 cites W2111191667 @default.
• W1970433797 cites W2119366998 @default.
• W1970433797 cites W2120669034 @default.
• W1970433797 cites W2120718661 @default.
• W1970433797 cites W2125195105 @default.
• W1970433797 cites W2129360604 @default.
• W1970433797 cites W2130254323 @default.
• W1970433797 cites W2132157071 @default.
• W1970433797 cites W2138157111 @default.
• W1970433797 cites W2139236349 @default.
• W1970433797 cites W2143859186 @default.
• W1970433797 cites W2145927385 @default.
• W1970433797 cites W2146404049 @default.
• W1970433797 cites W2148174696 @default.
• W1970433797 cites W2160040938 @default.
• W1970433797 cites W2161821474 @default.
• W1970433797 cites W2164183661 @default.
• W1970433797 cites W2165057455 @default.
• W1970433797 cites W2166084034 @default.
• W1970433797 cites W4247144993 @default.
• W1970433797 doi "https://doi.org/10.1097/jto.0b013e3181f1c8de" @default.
• W1970433797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20871269" @default.
• W1970433797 hasPublicationYear "2010" @default.
• W1970433797 type Work @default.
• W1970433797 sameAs 1970433797 @default.
• W1970433797 citedByCount "264" @default.
• W1970433797 countsByYear W19704337972012 @default.
• W1970433797 countsByYear W19704337972013 @default.
• W1970433797 countsByYear W19704337972014 @default.
• W1970433797 countsByYear W19704337972015 @default.
• W1970433797 countsByYear W19704337972016 @default.
• W1970433797 countsByYear W19704337972017 @default.
• W1970433797 countsByYear W19704337972018 @default.
• W1970433797 countsByYear W19704337972019 @default.
• W1970433797 countsByYear W19704337972020 @default.
• W1970433797 countsByYear W19704337972021 @default.
• W1970433797 countsByYear W19704337972022 @default.
• W1970433797 countsByYear W19704337972023 @default.
• W1970433797 crossrefType "journal-article" @default.
• W1970433797 hasAuthorship W1970433797A5001928949 @default.
• W1970433797 hasAuthorship W1970433797A5007889470 @default.
• W1970433797 hasAuthorship W1970433797A5012411744 @default.
• W1970433797 hasAuthorship W1970433797A5013804417 @default.
• W1970433797 hasAuthorship W1970433797A5016904876 @default.
• W1970433797 hasAuthorship W1970433797A5024585720 @default.
• W1970433797 hasAuthorship W1970433797A5030453966 @default.
• W1970433797 hasAuthorship W1970433797A5030827550 @default.
• W1970433797 hasAuthorship W1970433797A5036091074 @default.
• W1970433797 hasAuthorship W1970433797A5044573499 @default.
• W1970433797 hasAuthorship W1970433797A5044887899 @default.
• W1970433797 hasAuthorship W1970433797A5045442138 @default.
• W1970433797 hasAuthorship W1970433797A5046602426 @default.
• W1970433797 hasAuthorship W1970433797A5052004079 @default.

• next